網膜疾患治療の世界市場レポート 2024

網膜疾患治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.9%の年間複合成長率（CAGR）で179億3,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、網膜医療における患者中心のアプローチ、世界的な医療費の増加、網膜疾患に対する併用療法への注目の高まり、在宅網膜疾患モニタリングの台頭、網膜治療における移植可能デバイスの採用の増加、網膜治療における再生医療の採用などの要因に起因しています。予測期間中に予想される主な動向としては、眼科イメージング技術の進歩、低侵襲手術技術の開発、診断における人工知能の統合、薬物送達技術の進歩、網膜リハビリテーションにおけるバーチャルリアリティの統合、研究機関と製薬企業の提携、遺伝性網膜疾患に対する遺伝子治療の開発などが挙げられます。

予想される網膜疾患の有病率の増加は、網膜疾患治療市場の拡大を促進すると予想されます。網膜疾患には、目の奥にある光に敏感な組織である網膜に影響を及ぼす病状が含まれ、視力喪失や重度の視覚障害につながる可能性があります。レーザー治療、硝子体切除術、網膜インプラントなどの網膜疾患の治療は、症状の管理と軽減に重要な役割を果たします。 2023年 1月の時点で、国際失明予防機関は、加齢黄斑変性症（AMD）が世界の失明の約5%を占めると予測されていると報告しています。 AMDの罹患率は、2040年までに2億8,800万人に影響を与えると予想されています。したがって、網膜疾患の発生率の増加は、網膜疾患治療市場の成長の重要な推進力となります。

糖尿病の有病率の増加により、網膜疾患治療市場の成長がさらに促進されると予想されます。血糖値の上昇を特徴とする糖尿病は、糖尿病患者の間で最も一般的な網膜疾患である糖尿病性網膜症を引き起こす可能性があります。網膜の血管が損傷すると、出血、体液の漏出、新しい血管の発生が生じることがあります。このような合併症に対処するために、レーザー介入を含む網膜疾患治療が使用されます。 2021年 7月の時点で、国際糖尿病連盟は、2021年の世界の糖尿病人口は5億3,700万人で、2030年には6億4,300万人、2045年には7億8,300万人に増加すると予測しています。耐糖能異常の有病者数は、2021年までに5億4,100万人に達すると推定されています。したがって、糖尿病の増加は網膜疾患治療市場の成長の重要な推進力となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の網膜疾患治療市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 黄斑変性症
• 糖尿病性網膜症
• その他のタイプ
• 世界の網膜疾患治療市場、剤形別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ジェル
• アイソリューション
• カプセルと錠剤
• 目薬
• 軟膏
• 世界の網膜疾患治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• オンライン薬局
• 小売薬局

第7章 地域および国の分析

• 世界の網膜疾患治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の網膜疾患治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 網膜疾患治療市場の競合情勢
• 網膜疾患治療市場企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Novartis AG

第31章 その他の大手および革新的な企業

• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Genentech Inc.
• Santen Pharmaceutical Co. Ltd.
• Apellis Pharmaceuticals Inc.
• Kubota Pharmaceutical Holdings Co. Ltd
• Alimera Sciences Inc.
• Ocular Therapeutix Inc.
• EyePoint Pharmaceuticals Inc.
• Adverum Biotechnologies Inc.
• Kodiak Sciences Inc.
• Acucela Inc.
• IVERIC bio Inc.
• Oxurion NV

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Retinal disorder treatment encompasses medical interventions and procedures aimed at managing or improving the symptoms and conditions associated with retinal disorders. Retinal disorders involve abnormalities or damage to the retina, the light-sensitive tissue at the back of the eye responsible for transmitting visual signals to the brain.

The main types of retinal disorder treatment include macular degeneration, diabetic retinopathy, and others. Macular degeneration, often referred to as age-related macular degeneration (AMD), is a chronic eye condition primarily affecting the macula-the central area of the retina responsible for clear central vision. Treatment options are available in various dosage forms, including gels, eye solutions, capsules, tablets, eye drops, and ointments. These treatments are typically distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

The retinal disorder treatment market research report is one of a series of new reports from The Business Research Company that provides retinal disorder treatment market statistics, including the retinal disorder treatment industry's global market size, regional shares, competitors with a retinal disorder treatment market share, detailed retinal disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinal disorder treatment industry. This retinal disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The retinal disorder treatment market size has grown rapidly in recent years. It will grow from $11.57 billion in 2023 to $12.74 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The observed growth during the historical period can be attributed to factors such as the introduction of anti-VEGF therapies, an aging population, increased incidence of retinal disorders, improved diagnostic tools for early detection, increased awareness and screening programs, and expanded access to healthcare services.

The retinal disorder treatment market size is expected to see strong growth in the next few years. It will grow to $17.93 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The anticipated growth in the forecast period can be attributed to factors such as patient-centric approaches in retinal healthcare, increasing global healthcare expenditure, a greater focus on combination therapies for retinal disorders, the rise of home-based retinal disorder monitoring, the increasing adoption of implantable devices for retina treatment, and the adoption of regenerative medicine in retina treatment. Major trends expected in the forecast period include advancements in ophthalmic imaging technologies, the development of minimally invasive surgical techniques, the integration of artificial intelligence in diagnostics, advancements in drug delivery technologies, the integration of virtual reality in retinal rehabilitation, collaborations between research institutions and pharmaceutical companies, and the development of gene therapies for genetic retinal diseases.

The anticipated increase in the prevalence of retinal disorders is set to drive the expansion of the retinal disorder treatment market. Retinal diseases encompass medical conditions affecting the retina, the light-sensitive tissue at the back of the eye, and can lead to vision loss or severe visual impairment. Treatments for retinal disorders, including laser therapy, vitrectomy, and retinal implants, play a crucial role in managing and alleviating symptoms. As of January 2023, the International Agency for the Prevention of Blindness reports that age-related macular degeneration (AMD) is projected to account for approximately 5% of global blindness. The prevalence of AMD is expected to impact 288 million individuals by the year 2040. Thus, the rising incidence of retinal disorders is a significant driver for the growth of the retinal disorder treatment market.

The increasing prevalence of diabetes is anticipated to further bolster the growth of the retinal disorder treatment market. Diabetes, characterized by elevated blood glucose levels, can lead to diabetic retinopathy, the most common retinal disorder among individuals with diabetes. Damage to blood vessels in the retina can result in bleeding, fluid leakage, and the development of new blood vessels. Retinal disorder treatments, including laser interventions, are employed to address such complications. As of July 2021, the International Diabetes Federation projects a global diabetic population of 537 million in 2021, rising to 643 million in 2030 and 783 million in 2045. The prevalence of impaired glucose tolerance is estimated to reach 541 million by 2021. The increasing incidence of diabetes is thus a key driver for the growth of the retinal disorder treatment market.

A notable trend gaining traction in the retinal disorder treatment market is the innovation of products by major companies. These innovations are introduced to maintain a competitive edge in the market. For example, in January 2022, F. Hoffmann-La Roche AG, a pharmaceutical company based in Switzerland, received FDA approval for Vabysmo. Vabysmo is a bispecific antibody designed to treat neovascular or wet age-related macular degeneration (AMD) and diabetic macular edema (DME). It represents the first injectable eye medication targeting and inhibiting two disease pathways, Angiopoietin-2 (Ang-2) and Vascular Endothelial Growth Factor-A (VEGF-A), associated with retinal diseases. Clinical trials demonstrated non-inferior vision improvements compared to traditional therapy, with a favorable safety profile.

Major companies in the retinal disorder treatment market are actively developing innovative products, including treatments for geographic atrophy, to expand their customer bases, boost sales, and increase revenue. Geographic atrophy treatments focus on symptom management, disease progression mitigation, and aiding individuals in coping with visual impairment. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY. As a novel complement C5 inhibitor, IZERVAY is the sole approved treatment for geographic atrophy (GA) showing a statistically significant reduction (p<0.01) in the rate of GA progression in two Phase 3 clinical trials. This distinction positions IZERVAY as an effective therapy for GA secondary to age-related macular degeneration (AMD).

In July 2023, Astellas Pharma Inc. acquired Iveric Bio Inc., a biopharmaceutical company based in the United States, for an undisclosed amount. This strategic acquisition is aimed at expanding Astellas' presence in ophthalmology, gaining access to innovative therapies for retinal diseases, and enhancing its position in the market for treating ophthalmologic conditions and vision loss.

Major companies operating in the retinal disorder treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, Alimera Sciences Inc., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Adverum Biotechnologies Inc., Kodiak Sciences Inc., Acucela Inc., IVERIC bio Inc., Oxurion NV, Graybug Vision Inc., Icon Bioscience Inc., Clearside Biomedical Inc., Aerpio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Ophthotech Corporation, Opthea Limited, PanOptica Inc., ThromboGenics NV

North America was the largest region in the retinal disorder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the retinal disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The retinal disorder treatment market includes revenues earned by entities by providing retinal detachment, laser treatment, genetic treatments, and photodynamic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Retinal Disorder Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinal disorder treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for retinal disorder treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The retinal disorder treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Macular Degeneration; Diabetic Retinopathy; Other Types
• 2) By Dosage Form: Gels; Eye Solutions; Capsules And Tablets; Eye Drops; Ointments
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Retinal Disorder Treatment Market Characteristics

3. Retinal Disorder Treatment Market Trends And Strategies

4. Retinal Disorder Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Retinal Disorder Treatment Market Size and Growth

• 5.1. Global Retinal Disorder Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Retinal Disorder Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Retinal Disorder Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Retinal Disorder Treatment Market Segmentation

• 6.1. Global Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Macular Degeneration
• Diabetic Retinopathy
• Other Types
• 6.2. Global Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Gels
• Eye Solutions
• Capsules And Tablets
• Eye Drops
• Ointments
• 6.3. Global Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

7. Retinal Disorder Treatment Market Regional And Country Analysis

• 7.1. Global Retinal Disorder Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Retinal Disorder Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Retinal Disorder Treatment Market

• 8.1. Asia-Pacific Retinal Disorder Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Retinal Disorder Treatment Market

• 9.1. China Retinal Disorder Treatment Market Overview
• 9.2. China Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Retinal Disorder Treatment Market

• 10.1. India Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Retinal Disorder Treatment Market

• 11.1. Japan Retinal Disorder Treatment Market Overview
• 11.2. Japan Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Retinal Disorder Treatment Market

• 12.1. Australia Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Retinal Disorder Treatment Market

• 13.1. Indonesia Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Retinal Disorder Treatment Market

• 14.1. South Korea Retinal Disorder Treatment Market Overview
• 14.2. South Korea Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Retinal Disorder Treatment Market

• 15.1. Western Europe Retinal Disorder Treatment Market Overview
• 15.2. Western Europe Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Retinal Disorder Treatment Market

• 16.1. UK Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Retinal Disorder Treatment Market

• 17.1. Germany Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Retinal Disorder Treatment Market

• 18.1. France Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Retinal Disorder Treatment Market

• 19.1. Italy Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Retinal Disorder Treatment Market

• 20.1. Spain Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Retinal Disorder Treatment Market

• 21.1. Eastern Europe Retinal Disorder Treatment Market Overview
• 21.2. Eastern Europe Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Retinal Disorder Treatment Market

• 22.1. Russia Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Retinal Disorder Treatment Market

• 23.1. North America Retinal Disorder Treatment Market Overview
• 23.2. North America Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Retinal Disorder Treatment Market

• 24.1. USA Retinal Disorder Treatment Market Overview
• 24.2. USA Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Retinal Disorder Treatment Market

• 25.1. Canada Retinal Disorder Treatment Market Overview
• 25.2. Canada Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Retinal Disorder Treatment Market

• 26.1. South America Retinal Disorder Treatment Market Overview
• 26.2. South America Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Retinal Disorder Treatment Market

• 27.1. Brazil Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Retinal Disorder Treatment Market

• 28.1. Middle East Retinal Disorder Treatment Market Overview
• 28.2. Middle East Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Retinal Disorder Treatment Market

• 29.1. Africa Retinal Disorder Treatment Market Overview
• 29.2. Africa Retinal Disorder Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Retinal Disorder Treatment Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Retinal Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Retinal Disorder Treatment Market Competitive Landscape And Company Profiles

• 30.1. Retinal Disorder Treatment Market Competitive Landscape
• 30.2. Retinal Disorder Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. AbbVie Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Retinal Disorder Treatment Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Bausch Health Companies Inc.
• 31.4. Genentech Inc.
• 31.5. Santen Pharmaceutical Co. Ltd.
• 31.6. Apellis Pharmaceuticals Inc.
• 31.7. Kubota Pharmaceutical Holdings Co. Ltd
• 31.8. Alimera Sciences Inc.
• 31.9. Ocular Therapeutix Inc.
• 31.10. EyePoint Pharmaceuticals Inc.
• 31.11. Adverum Biotechnologies Inc.
• 31.12. Kodiak Sciences Inc.
• 31.13. Acucela Inc.
• 31.14. IVERIC bio Inc.
• 31.15. Oxurion NV

32. Global Retinal Disorder Treatment Market Competitive Benchmarking

33. Global Retinal Disorder Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Retinal Disorder Treatment Market

35. Retinal Disorder Treatment Market Future Outlook and Potential Analysis

• 35.1 Retinal Disorder Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Retinal Disorder Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Retinal Disorder Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer